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The Obesity-associated fat mass (FTO) gene has been associated to a higher risk of obstetri-
cal complications. 
The aim of this prospective, cross-sectional and comparative study was to determine if there 
are clinical or laboratorial differences in pregnant women with the presence/absence of FTO 
rs9939609 focused on threatened abortion.
Pregnant women between 18 to 35 years of age were invited to participate. In all cases, it was 
obtained the sociodemographic information, anthropometry, clinical laboratories for obstetrical rou-
tine check-up, FTO rs9939609 positive expression, and the homeostasis model assessment (HOMA) 
and the quantitative insulin sensitivity check index (QUICKI) indexes were also calculated.
Comparisons of this type of variables between both groups were performed through Student´s 
T-test. Chi-Square Tests were used to contrast the GDM and threatened miscarriages percent-
ages of cases between both groups. Pearson correlation was performed among the quantitative 
variables of all the study population.
57 women positive and 52 negative for the FTO rs9939609 presence were included in the 
study with a Gestational Diabetes Mellitus prevalence of 19.3%. When contrasting the variables 
by the presence/absence of FTO rs9939609 the p-values were far from being significant. As such, 
Chi-Square Tests did not show significant statistical difference neither for GDM nor for threat-
ened miscarriage between both groups.
Based on these results, the FTO rs9939609 presence did not reflect difference either in GDM 
or in threatened miscarriage. It was demonstrated in parallel, the utility of the QUICKI index in 
the metabolic evaluation during pregnancy. In conclusion, in Mexican women, pregnancy evolu-
tion and possible appearance of complications is not so determined by the FTO rs9939609 pres-
ence but by the overweight with which this physiological state is faced.
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to encode the production of a nuclear protein 
with nucleic acid demethylase activity [Chen 
J, Du B, 2019]. Its action has been related to 
various biochemical and physiological pro-
cesses, including influence on body composi-
tion through playing a role in cellular nutrient 
sensing [Gulati P, et al, 2013], DNA repair 
[Jia G, et al, 2008], regulation of lipid storage 
and adipose tissue [Zhao X, et al, 2014], etc. 
iNTroducTioN
The fat mass and obesity-associated gene 
(FTO) is located on chromosome 16 (16q12.2) 
[Fang H, et al, 2010] and has been determined 
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The FTO presence has been associated to a 
higher risk of metabolic syndrome parameters 
in adolescence as well as with weight gain/
obesity [Martínez-Martínez MA, et al, 2018; 
Kalantari N, et al, 2018]. FTO mutations lead 
to extensive phenotypic modifications includ-
ing various congenital malformations and 
delay in physical and psychomotor growth 
[Rohena L, et al, 2016; Howard SR, 2019]. 
FTO polymorphism (SNPs) have been investi-
gated extensively in populations with obesity 
[Zhang Q, et al, 2018; Daya M, et al, 2019], 
and specifically, the rs9939609 variant has 
also been linked to the increased risk of diabe-
tes mellitus [Jiménez-Osorio AS, et al, 2019]. 
Table 1 shows some diseases associated with 
the presence of this last SNP.
More recently the association of this SNP 
with a higher risk to develop Gestational Dia-
betes Mellitus (GDM) has also been studied in 
several surveys with contrasting results [He H, 
et al, 2018; Lin Z, et al, 2018]. The aim of this 
study was to determine if there are clinical or 
laboratorial differences in pregnant women 
with the presence/absence of FTO rs9939609 
with focused on threatened abortion.
mATeriAl ANd meThodS
This was a prospective, cross-sectional and 
comparative study performed at the “Mónica 
Pretelini Sáenz” Maternal Perinatal Hospital 
(HMPMPS), Health Institute of the State of 
Mexico (ISEM), Toluca, Mexico. 
Patients; Pregnant women between 18 to 
35 years of age were invited to participate, ex-
plaining them in detail the project, and asking 
to sign the consent form according to the cur-
rent Clinical Practice Guideline. Those women 
with a history of smoking or alcoholism, 
chronic or autoimmune diseases were ex-
cluded from the final analysis.
Sampling: Accepting an alpha risk of 0.05 
and a beta risk of 0.2 in a two-sided test, 45 
pregnant women per group were necessary for 
a percentage of threatened abortion of 5% in 
the GDM group [Pacora Portella P, et al, 
1991] and a hypothetical 25% in the FTO 
rs9939609 group.
General data: General data including he-
reditary-family history was collected by means 
of a medical history comprising and personal 
interview; as well as complementary data of 
nutritional habits and physical activity.
anthropometry weight (kg), fat mass (kg), 
muscle mass (kg), corporal water (%) and met-
abolic age (ages) were calculated using Tanita 
(model BC-533, Tanita, Tokyo, Japan), height 
(m) was measured with conventional stadiom-
eter and the Body Mass Index (BMI) was cal-
culated as standard (kg/m2). The gestational 
BMI classification was done according to 
world Health Organization (wHO) cutoffs 
(underweight [<18.5 kg/m2], normal weight 
[18.5–24.9 kg/m2], overweight [25.0–29.9 kg/
m2], and obesity [≥30.0 kg/m2]) [WHO, 2019].
In addition, more clinical parameters, in-
cluding gestational weight gain (kg) and blood 
pressure (mmHg) were also registered. Hand 
grip strength (HGS) was measured by a dyna-
mometer (Takei Scientific Instruments Co., 
Ltd., Niigata-City, Japan). 
laboratory: Venous blood 
samples were taken after an 
8-hour fasting period to process 
glucose and insulin curves. The 
GDM diagnosis was based on 
an abnormal 75 g oral glucose 
tolerance test (OGTT) where ei-
ther one or more blood glucose 
values were above the values of 
5.1 mmol/L (92 mg/dL) at fast-
TABle 1. 
Some diseases associated with the presence 
of ftO rs9939609
Source Disorder
Khella MS et al., (2018) Malignant Pleural Mesothelioma
Huang x et al., (2017) Cancer
Yu JH et al., (2017) Biological aging
Castellini G et al., (2017) Eating disorders susceptibility
Barton SJ  et al., (2016) Fetal growth trajectories







To overcome it 
is possible, due to the 
uniting the knowledge and 
will of all doctors in the world
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ing, 10.0 mmol/L (180 mg/dL) at 1 h, and 
8.5mmol/L (153 mg/dL) at 2 h. At the same 
time, the insulin curve was quantified and with 
this information, the homeostasis model as-
sessment (HOMA) and the quantitative insulin 
sensitivity check index (QUICKI) indexes 
were calculated for all women.
Genotyping: In the Genetics Laboratory of 
the Faculty of Medicine, Autonomous Univer-
sity of the State of Mexico (UAEMex), DNA 
was extracted, quantified with a spectropho-
tometry (NanoPhotometer, Implen), and kept 
at -70°C until SNP identification.
Genotyping was performed by real-time 
polymerase chain reaction (qPCR) in the Re-
search Laboratory of Ciprés Grupo Médico 
(CGM) in a PrimeQ (Techne, UK) equipment. 
The FTO rs9939609 oligonucleotides used in 
this study were those described previously by 
Yan Q [Yan Q, et al, 2009], forward primer 
5’-CAAAACTGGCTCTTGAATGAA-3’ and 
the reverse primer 5’-TGTCCAAACAGTAG-
GTCAGGA-3’; requested at the DNA Synthe-
sis and Sequencing Unit of the National Au-
tonomous University of Mexico (UNAM), In-
stitute of Biotechnology (Cuernavaca, More-
los, Mexico) with a previous BLAST search to 
verify the correct hybridization and following 
the conditions of the same author.
bioethical implications: The Research 
Committee and the Ethics in Research Com-
mittee of the HMPMPS (2017-06-S29) as 
well as by the Research and Ethics Commit-
tee of the Medical Sciences Research Center 
(CICMED), UAEMéx (CIE2018-1), autho-
rized this protocol.
The procedures were carried out under the 
deontological norms of the Declaration of Hel-
sinki (2013 Fortaleza, Brazil) and of the Gen-
eral Health Law (Mexico), regarding health 
research. All participants were informed about 
the purpose of the study, risks and benefits and 
were given the informed consent letter for 
their signature.
Statistical analysis: Quantitative variables 
were represented in mean ± Standard deviation 
(SD). Comparisons of this type of variables be-
tween both groups were performed through 
Student´s T-test. Chi-Square Tests were used to 
contrast the percentages of cases of GDM and 
threatened miscarriage between both groups. 
Pearson correlation was performed among the 
quantitative variables of all the study popula-
tion. The one-way ANOVA test was used to 
contrast the values of the quantitative variables 
per BMI classification of the patients and inde-
TABle 2. 








Age (years) 26.46 ± 6.59 25.60 ± 6.90 0.924
Gestational 
age (weeks) 26.4 ± 2.6 27.0 ± 2.3 0.155
Cardiac 
frequency 84.21 ± 11.45 85.42 ± 10.13 0.554
weight (kg) 71.16 ± 14.23 68.58 ± 13.24 0.332
Height (m) 1.55 ± 0.06 1.54 ± 0.06 0.771
BMI (kg/m2) 29.45 ± 5.24 28.54 ± 5.01 0.525
Fat mass (kg) 36.82 ± 7.29 35.19 ± .80 0.231
Muscle mass 
(kg) 41.78 ± 4.23 41.42 ± 4.43 0.668
Bone mass 
(kg) 2.22 ± 0.20 2.21 ± 0.23 0.828
Glucometry 
(mg/dL) 84.87 ± 10.89 86.48 ± 11.45 0.768
Basal glucose 








30.67 107.36 ± 36.39 0.730
Basal insulin 
(µU/mL) 13.30 ± 6.40 16.03 ± 12.10 0.139
Insulin 60 min 
(µU/mL) 50.91 ± 57.62 53.70 ± 45.98 0.782
Insulin 120 
min (µU/mL) 43.24 ± 46.53 46.84 ± 36.41 0.656
HOMA-IR 2.85 ± 1.59 3.44 ± 3.04 0.203
QUICKI 0.33 ± 0.02 0.33 ± 0.4 0.613
SBP (mmHg) 107.7 ± 10.52 104.32 ± 9.98 0.088
DBP (mmHg) 65.57 ± 9.57 64.28 ± 7.57 0.440
HGS right (kg) 24.07 ± 5.74 24.75 ± 4.71 0.503
HGS left (kg) 22.49 ± 6.01 22.69 ± 4.10 0.840
NoTeS: Data are expressed as mean ± SD., bMi: 
Body Mass Index, dbP: Diastolic Blood Pressure, 
hGS: Handgrip strength testing, SbP: Systolic 
Blood Pressure.
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pendent sample Student’s t-tests or the Mann 
whitney U tests were used to do multiple com-
parisons between groups for all BMI classes. In 
all cases it was used the SPSS v21 statistical 
package with a level of significance of p ≤ 0.05.
reSulTS
57 women positive and 52 negative for the 
FTO rs9939609 presence were included in the 
study with a prevalence GDM of 19.3%. The 
general characteristics of included patients are 
depicted in Table 2. After performing the Kol-
mogorov test, all the quantitative variables 
were confirmed to have parametric distribu-
tions. 
The nutritional classification in the first medi-
cal visit reported the following distribution: Un-
dernutrition = 8, Normal weight = 37, Over-
weight = 34, Obesity =30. when contrasting 
the variables per classification of BMI, besides 
the expected differences in fat, muscle and 
bone masses, there were differences in the 
HGS of both hands between underweight and 
overweight women (p = 0.008 left, p ≤ 0.001 
right), observed only in the right HGS between 
underweight and obese women (p ≤ 0.05) and 
in both sides again between normal-weight 
and overweight pregnant women (p ≤ 0.05).
when contrasting 
the variables by the 
presence/absence of 
FTO rs9939609 the p-
values were far from 
being significant. As 
such, Chi-Square Tests 
did not show signifi-
cant statistical differ-
ence neither for GDM 
nor for threatened mis-




showed that BMI, fat 
mass, muscle mass, 
body water, bone mass 
and metabolic age were 
positively correlated 
with capillary glucose, 
systolic blood pressure, HGS (both sides), 
kcal, basal glucose and glucose in the 1st and 
2nd hour post 75 g oral glucose test (Table 3). It 
calls the attention that the QUICKI index had 
a significant negative correlation with 12 pa-
rameters, while HOMA index had positive 
correlation with only seven (Table 4).
diScuSSioN
Adding to what has been reported repeat-
edly [He H, et al, 2018; Guo F, et al, 2018] our 
study did not show a correlation between the 
FTO rs9939609 presence and GDM develop-
ment. Although FTO has been associated with 
high gestational weight gain in obese black 
women who have either risk variant [Groth 
SW, et al, 2018] in our community black 
women are few and no one was attended in the 
Hospital during our screening phase. 
whereas some authors have shared infor-
mation about an association between FTO 
(or variants) with  lipid parameters [Fran-
zago M, et al, 2018]; nevertheless, our study 
evidenced a lack of association of these 
variables. In a similar way, it has been dem-
onstrated that some polymorphisms related 



















Fat mass (kg) 0.871ϒ
Muscle Mass (kg) 0.780ϒ 0.725ϒ
Body water (%) -0.858ϒ -0.997ϒ -0.676ϒ
Bone Mass (%) 0.788ϒ 0.715ϒ 0.961ϒ -0.670ϒ
Metabolic Age (years) 0.785ϒ 0.912ϒ 0.673ϒ -0.913ϒ 0.658ϒ
CG (mg/dl) 0.359ϒ 0.314ϒ 0.230 -0.317ϒ 0.233* 0.251†
SBP (mmHg) 0.326ϒ 0.354ϒ 0.342ϒ -0.344ϒ 0.330ϒ 0.299†
HGS  Left (kg) 0.192* 0.252† 0.339ϒ -0.240* 0.304ϒ 0.242*
HGS Right (kg) 0.207* 0.280† 0.348ϒ -0.268* 0.307ϒ 0.271†
kcal 0.676ϒ 0.688ϒ 0.891ϒ -0.641ϒ 0.860ϒ 0.592ϒ
Glucose (mg/dl) 0.393ϒ 0.299† 0.205 -0.302ϒ 0.226* 0.241*
Glucose H1 (mg/dl) 0.403ϒ 0.358ϒ 0.216 -0.369ϒ 0.243* 0.351ϒ
Glucose H2 (mg/dl) 0.417ϒ 0.357ϒ 0.225 -0.366ϒ 0.252† 0.372ϒ
noteS: bMi: Body Mass Index, cG: Capillary Glucose, hGS: Handgrip 
strength testing, SbP: Systolic Blood Pressure. *≤ 0.05  †≤ 0.01 ϒ≤ 0.001
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TABle 4. 
Significant correlation of HoMA and QUiCKi 
indexes with all the variables
 HoMA QUiCKi
BMI (kg/m2) -0.249†
Muscle Mass (kg) -0.202*
Bone Mass (kg) -0.198*
Capillary Glucose (mg/dl) 0.380ϒ -0.366ϒ
Basal Glucose (mg/dl) 0.589ϒ -0.671ϒ
Glucose H1 (mg/dl) 0.411ϒ -0.445ϒ
Glucose H2 (mg/dl) 0.349ϒ -0.414ϒ
Basal Insulin (IU) 0.959ϒ -0.764ϒ
Insulin H1 (IU) 0.439ϒ -0.436ϒ
Insulin H2 (IU) 0.372ϒ -0.415ϒ
FATMSKg -0.205*
HOMA -0.766ϒ
NoTeS: bMi: Body Mass Index, h1: 1st hour after 75 g 
of oral glucose, h2: 2nd hour after 75 g oral glucose, 
hOMa: homeostasis model assessment, QuicKi: 
quantitative insulin sensitivity check index.  *≤ 0.05, 
†≤ 0.01, ϒ≤ 0.001
lated to the HOMA-IR marker of insulin re-
sistance [Smith CE, et al, 2012; De Luis DA, 
et al, 2016] but in the two groups studied 
there was not a difference. 
Research concerning mothers’ FTO 
rs9939609 has confirmed an impact on birth 
weight and newborns’ BMI of this SNP, a role 
in the newborns’ nutritional status [Mărginean 
C, et a, 2016]. Unfortunately, it was not pos-
sible to attend all women in our Hospital so 
the information of the babies’ weight and 
height was missing to make any association 
with the SNP presence.
A previous study controlling for important 
factors such as BMI, diabetes and cardiovas-
cular disease showed that FTO rs9939609 SNP 
was associated with recurrent miscarriage 
[Andraweera PH, et al, 2015] and two more 
putative undesired effects of FTO rs9939609 
SNP are an association with lower fetal growth 
[Marsh JA, et al, 2012] and spontaneous pre-
term birth [Andraweera PH, et al, 2016].
SNPs have been reported that depending 
on the interaction with environmental and 
nutritional factors are considered responsi-
ble for the onset of various diseases such as 
obesity and diabetes, or are the trigger for 
the development of such diseases. But this 
genetic interaction is most often not specific 
to a single SNP, but is the result of the inter-
action of various genes and individuality of 
each person [Wang YT, et al, 2015]. To make 
it more difficult, some effects can be dis-
creet, indirect and identifiable in the long 
term, for example, FTO rs9939609 has been 
linked to systemic inflammation, which is 
related in processes of diabetogenesis and 
insulin resistance [Saucedo R, et al, 2017].
The present study has some limitations. 
First, the sample size for the SNP was rela-
tively small. Second, abdominal fat of preg-
nant women was not measured. However, 
the results may be relevant to the extent of 
knowledge about the handicap of Mexican 
women since the beginning of pregnancy 
attributed to overweight/obesity [Díaz 
Montiel JC, et al, 2019].
Further studies are required to explore the 
specific association of the FTO rs9939609 al-
leles with all the variables studied or even con-
sider more genes with their variants and of course 
additional analyses, such as epigenetic studies, 
to elucidate the role of the own fetal genes and 
alleles in the development and prognosis of met-
abolic diseases and obstetrical complications.
coNcluSioN
FTO rs9939609 presence did not lead to a 
higher percentage of cases neither of GDM 
nor of threatened miscarriage. Another impor-
tant observation was that QUICKI index seems 
to be more useful than HOMA index to check-
up the metabolic status during pregnancy.
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